Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships

This community-based initiative is designed to leverage the insights and experience of local and national HCV, HIV, and policy experts in the setting of small-group, peer-to-peer education. The purpose of this series of live, regional, multidisciplinary educational interventions is to build connections across local and regional care networks to optimize the identification and treatment of patients with HCV, specifically in the context of HIV/HCV coinfection.

initiative goals

Discuss how the existing HIV-treatment infrastructures can facilitate treatment of HCV among co-infected patients
Identify barriers to HCV elimination relative to local/regional circumstances
Share success stories and best-practices from established care models in other geographic and therapeutic areas
Build linkage-to-care networks within local/regional systems
Begin the establishment of a roadmap specific to regional needs and resources for HCV elimination in HIV/HCV co-infected patients

Program Description

Approximately 25% of all individuals infected with HIV are coinfected with HCV.1 Of critical significance, HIV increases the rate of progression of HCV-related hepatic fibrosis, and HCV is associated with a 3-fold increase in HIV antiretroviral therapy (ART)–induced liver toxicity.2 Further, these synergistic diseases often occur within adverse socioeconomic conditions that significantly increase the vulnerability and decrease the overall health status of at-risk populations.3 Whereas HIV infection is now effectively manageable, chronic HCV infection is curable. Yet, despite new, highly effective direct-acting antiviral (DAA) treatment regimens for HCV, their broad-scale use and associated therapeutic successes remain stymied by barriers at the patient, clinician, health care system, and jurisdictional levels.4 The BLOCK HIV/HCV initiative will provide community-based infectious disease specialists and other HIV treaters with foundational information and practical resources needed to prepare local stakeholders—both clinical and nonclinical—to collaborate in efforts to eliminate HCV within their communities.

  1. Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis.
    Accessed January 24, 2018.
  2. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14(6):371-386.
  3. Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco, CA: Jossey-Bass; 2009.
  4. National Viral Hepatitis Roundtable (NVHR). Hepatitis C: The State of Medicaid Access. October 23, 2017. Accessed January 24, 2018.

educational objectives

After completing this activity, the participant should be better able to:

Describe epidemiologic trends in HCV monoinfection and HIV/HCV coinfection within at-risk populations, including men who have sex with men (MSM), people who inject drugs (PWID), and incarcerated individuals
Provide guideline-based treatment for HCV monoinfection and HIV/HCV coinfection
Identify patient, provider, and health care system barriers to effective management of HCV monoinfection and HIV/HCV coinfection
Implement strategies to overcome risk-cohort–specific challenges to the treatment of HCV
monoinfection and HIV/HCV coinfection

steering committee

David L. Wyles MD (Course Chair) 
Chief, Division of Infectious Diseases
Denver Health
Professor of Medicine
University of Colorado School of Medicine
Denver, Colorado

Cody A. Chastain, MD (Knoxville Co-Chair) 
Assistant Professor of Medicine
Viral Hepatitis Program
Division of Infectious Diseases
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Kenneth E. Sherman, MD, PhD (Cincinnati Co-Chair)
Distinguished Research Professor
Gould Professor of Medicine
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio

Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD
(Lansing Co-Chair)

Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health System
Detroit, Michigan

Mark S. Sulkowski, MD (Baltimore Co-Chair) 
Medical Director, Viral Hepatitis Center
Professor of Medicine
Johns Hopkins Medicine
Baltimore, Maryland

Stacey Trooskin, MD, PhD, MPH
Director, Viral Hepatitis Programs
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania

COVID-19 Prevention – What Precautions Are We Taking?

Your safety and health come first. Please know that we are keeping a close eye on the COVID-19 (Coronavirus) pandemic and we will continue to monitor the BLOCK program sites using updates and best guidance from the Centers for Disease Control and Prevention (CDC).

At this time, we are proceeding with the live, in-person events offered below. Attendance at each event will be limited to a maximum of 50 participants. All state-mandated safety precautions (at the time of the meeting) will be in place. Please continue to check this page and your email for updates regarding the specific program that you have registered for.


Lansing, MI

Monday, September 27, 2021

Radisson Hotel Lansing at the Capital
111 North Grand Avenue
Lansing, MI  48933


Lansing, MI

Details Coming Soon!


Cincinnati, OH

Friday, August 6, 2021

Knoxville, TN

Monday, April 12, 2021

Baltimore, MD

Friday, September 25, 2020

Richmond, KY

November 15, 2019

Birmingham, AL

October 18, 2019

Asheville, NC

September 23, 2019

Oakland, CA

September 13, 2019

Chicago, IL

June 24, 2019

Atlanta, GA

September 28, 2018

Boston, MA

September 17, 2018

Charleston, WV

June 12, 2018

Program Agenda

10 minutes

Welcome and Preactivity Polling

30 minutes

The Challenge of HCV Elimination

30 minutes

HCV Therapy: The State of the Union

20 minutes

Populations in Greatest Need—Men Who Have Sex With Men (MSM)

20 minutes


30 minutes

Populations in Greatest Need—People Who Inject Drugs (PWID)

20 minutes

Other Real-World Circumstances

20 minutes

Success Stories

30 minutes


30 minutes

Addressing Region-Specific Barriers and Challenges to HCV Elimination

10 minutes

Introduction to Small-Group Breakouts:
Bringing Together Stakeholders and Creating a Collaborative Plan

30 minutes

Multidisciplinary Small Groups: Putting a Plan Into Action

60 minutes

Panel Discussion: The Call to Action & Beyond

20 minutes

Closing Statements & Postactivity Polling


target audience

This activity is intended for a multidisciplinary audience including community-based infectious disease specialists and other HIV treaters, gastroenterology/hepatology clinicians, mental health specialists, substance abuse specialists, correctional health care professionals, public policy/public health officials, hepatitis C virus (HCV) and HIV advocacy groups, payers, and clinical office staff who are engaged in the care of patients with HIV and/or HCV.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 6.5 contact hours (0.65 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-20-2032-L05-P)

Type of activity


Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.  Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 6.5 contact hours.
Pharmacotherapy contact hours for Advanced Practice Registered Nurses to be determined. 

Social Worker and Case Manager credit will be applied for, but is not guaranteed at this time.

Social Worker Education

As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.  Organizations, not individual courses, are approved under this program.  State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit.  Postgraduate Institute for Medicine maintains responsibility for this course.  Social workers completing this course receive 6.5 clinical continuing education credits.

Case Manager Education

This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 6.5 clock hours.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as
related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. 
The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at

Fee Information

There is no fee for this educational activity.

2020/2021 Collaborators

2019 Collaborators

In collaboration with:

2018 Collaborators


For additional clinician and patient resources visit: